Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 26, 2017 - Issue 8
Submit an article Journal homepage
16,058
Views
177
CrossRef citations to date
0
Altmetric
Editorial

Do STAT3 inhibitors have potential in the future for cancer therapy?

Andrea L.A. WongDepartment of Haematology-Oncology, National University Health System, Singapore;Haematology-Oncology Research Group, National University Cancer Institute of Singapore, National University Health System, Singapore;Cancer Science Institute, SingaporeView further author information
,
Jayshree L. HirparaCancer Science Institute, SingaporeView further author information
,
Shazib PervaizDepartment of Physiology, Yong Loo Lin School of Medicine, National University of Singapore;NUS Graduate School for Integrative Sciences and Engineering, National University of SingaporeView further author information
,
Jie-Qing EuCancer Science Institute, SingaporeView further author information
,
Gautam SethiDepartment of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, SingaporeView further author information
&
Boon-Cher GohDepartment of Haematology-Oncology, National University Health System, Singapore;Haematology-Oncology Research Group, National University Cancer Institute of Singapore, National University Health System, Singapore;Cancer Science Institute, Singapore;Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, SingaporeCorrespondence[email protected]
View further author information
Pages 883-887 | Received 21 Apr 2017, Accepted 04 Jul 2017, Published online: 17 Jul 2017

References

  • Dimri S, Sukanya S, De A. Approaching non-canonical STAT3 signaling to redefine cancer therapeutic strategy. Integr Mol Med. 2017;4:1–10.
  • Koskela HL, Eldfors S, Ellonen P, et al. Somatic STAT3 mutations in large granular lymphocytic leukemia. N Engl J Med. 2012;366:1905–1913.
  • Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105.
  • Alvarez JV, Greulich H, Sellers WR, et al. Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. Cancer Res. 2006;66:3162–3168.
  • Becker TM, Boyd SC, Mijatov B, et al. Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor. Oncogene. 2014;33:1158–1166.
  • Lee HJ, Zhuang G, Cao Y, et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell. 2014;26:207–221.
  • Yu CR, Kim SH, Mahdi RM, et al. SOCS3 deletion in T lymphocytes suppresses development of chronic ocular inflammation via upregulation of CTLA-4 and expansion of regulatory T cells. J Immunol. 2013;191:5036–5043.
  • Harrison C, Kiladjian JJ, Al-Ali HK, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med. 2012;366:787–798.
  • Turkson J, Kim JS, Zhang S, et al. Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity. Mol Cancer Ther. 2004;3:261–269.
  • Wong AL, Soo RA, Tan DS, et al. Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies. Ann Oncol. 2015;26:998–1005.
  • Murakami T, Takigawa N, Ninomiya T, et al. Effect of AZD1480 in an epidermal growth factor receptor-driven lung cancer model. Lung Cancer. 2014;83:30–36.
  • Hong D, Kurzrock R, Kim Y, et al. AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer. Sci Transl Med. 2015;7:314ra185.
  • Sen M, Thomas SM, Kim S, et al. First-in-human trial of a STAT3 decoy oligonucleotide in head and neck tumors: implications for cancer therapy. Cancer Discov. 2012;2:694–705.
  • Fontaine F, Overman J, Francois M. Pharmacological manipulation of transcription factor protein-protein interactions: opportunities and obstacles. Cell Regen (Lond). 2015;4:2.
  • Furqan M, Akinleye A, Mukhi N, et al. STAT inhibitors for cancer therapy. J Hematol Oncol. 2013;6:90.
  • Myers MG Jr. Cell biology. Moonlighting in mitochondria. Science. 2009;323:723–724.
  • Gu L, Talati P, Vogiatzi P, et al. Pharmacologic suppression of JAK1/2 by JAK1/2 inhibitor AZD1480 potently inhibits IL-6-induced experimental prostate cancer metastases formation. Mol Cancer Ther. 2014;13:1246–1258.
  • Chai EZ, Shanmugam MK, Arfuso F, et al. Targeting transcription factor STAT3 for cancer prevention and therapy. Pharmacol Ther. 2016;162:86–97.
  • Poli V, Camporeale A. STAT3-mediated metabolic reprograming in cellular transformation and implications for drug resistance. Front Oncol. 2015;5:121.
  • Wan J, Fu AK, Ip FC, et al. Tyk2/STAT3 signaling mediates beta-amyloid-induced neuronal cell death: implications in Alzheimer’s disease. J Neurosci. 2010;30:6873–6881.
  • Schonberg K, Rudolph J, Vonnahme M, et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 2015;75:2187–2199.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.